Foley Partner David Rosen was quoted in an article that appeared in Genetic Engineering & Biotechnology News on October 12, 2011 titled “Extent of Feedback on RUO/IUO In Vitro Dx Draft Guidance Means Changes Not Expected Soon.” Rosen discusses draft guidance proposed by the FDA concerning the labeling of in vitro diagnostic (IVD) products marked “for research use only” (RUO) and “for investigational use only” (IUO). He states that some companies are concerned about what products they can sell as RUO/IUO tests and what they cannot under the FDA’s draft guidelines. Rosen recognizes the need for research, but notes that it is also important to ensure that people do not rely on tests that are not verified and validated.
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"